Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 91, Issue 9, 1996, Pages 1766-1772

  Richter, Joel E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; METOCLOPRAMIDE; OMEPRAZOLE; RANITIDINE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERANCE; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; TREATMENT PLANNING;

DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; METOCLOPRAMIDE; MIDDLE AGED; OMEPRAZOLE; RANITIDINE; TIME FACTORS;

EID: 0029840751     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Dent J, Holloway RH, Toouli J, et al. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastroesophageal reflux. Gut 1988;29:1020-8.
2. Howden CW. Appropriate acid suppression in the treatment of acidrelated conditions. Pharmacol Ther 1994;63:123-34.